Hinova Pharmaceuticals released its semi-annual performance, with a net loss attributable to the parent company of 61.85 million yuan
I'm PortAI, I can summarize articles.
Hinova released its 2025 semi-annual report, with revenue of 13.17 million yuan, a year-on-year increase of 11,899.08%. The net loss attributable to the parent company was 61.85 million yuan, and the net profit excluding non-recurring items was a loss of 73.01 million yuan, with basic earnings per share of -0.62 yuan. The significant revenue growth was mainly due to the launch of the new drug deuterated enzalutamide soft capsules, with sales revenue reaching 13.0688 million yuan
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments